ClinicalTrials.gg
TerminatedNCT00290771Updated May 16, 2011Results posted

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

A Phase 2 interventional study of Imatinib tablets and Hydroxyurea capsules in Recurrent Glioblastoma Multiforme (GBM), sponsored by Novartis. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-16.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Why this study was terminated
Lack of efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
231
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing imatinib in Glioblastoma — none open to participants now, none under way, none of them phase 3. imatinib · Glioblastoma.

Enrollment
2nd of 10
231 · median 65
Started
2006
with 2 others
Phase 2
5 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
Novartis

Among the 10 studies testing imatinib in Glioblastoma, this one is the 2nd largest by enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 5th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

None of the 10 studies testing imatinib in Glioblastoma is open now. The open studies under Glioblastoma, anywhere →

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing imatinib in Glioblastoma as a file.
02

Study summary

This was an investigational study to assess the objective overall response (OOR) rate (complete response [CR] + partial response [PR]) of imatinib mesylate and hydroxyurea (hydroxycarbamide) combination therapy in patients with recurrent glioblastoma multiforme (brain tumors). This study also evaluated the duration of tumor response (as per MacDonald criteria), clinical benefit, progression-free survival rate at 6 and 12 months, and the survival rate at 12 and 24 months.

Read the detailed description

This ClinicalTrials.gov record includes the results from two studies (Novartis protocol IDs CSTI571H2201 and CSTI571H2202) which were conducted separately but reported together in a single clinical study report. Both studies were phase II, open-label, multicenter, single-arm studies that evaluated the efficacy of imatinib mesylate plus hydroxyurea in subjects with progressive glioblastoma multiforme. The studies were identical in design with two exceptions: Patients in study CSTI571H2201 received a dose of imatinib 600 mg once daily and were not allowed concomitant use of enzyme-inducing anticonvulsant drugs (EIACDs); patients in study CSTI571H2202 received a dose of imatinib 500 mg twice daily and were allowed concomitant use of EIACDs.

03

Conditions studied

  • Recurrent Glioblastoma Multiforme (GBM)

Keywords

  • imatinib mesylate
  • hydroxyurea
  • protein tyrosine kinases
  • glioma
  • glioblastoma multiforme
  • recurrent glioblastoma multiforme
  • GBM
  • MacDonald criteria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ≥ 18 years old.
  • -confirmed diagnosis of progressive primary glioblastoma multiforme (GBM) based on original diagnosis. Patients with prior low-grade glioma were eligible if histological re-assessment demonstrated transformation to GBM.
  • No more than one prior episode of progressive disease following previously received surgery and/or radiation and only one prior chemotherapy exposure of either temozolomide (TMZ) or nitrosourea including the application of polifeprosan (Gliadel®) wafers.
  • Presence of on gadolinium-enhanced magnetic resonance imaging (MRI).
  • Patients taking must have been on a stable dose for ≥ 7 days.
  • (ECOG) performance score ≤ 2.
  • ≥ 10 g/dL (or hematocrit > 29%), (ANC) > 1500 cells/L, > 100,000 cells/L.
  • Serum creatinine \< 1.5 mg/dL, blood urea nitrogen (BUN) \< 25 mg/dL, serum (AST) and \< 1.5 x (ULN).
  • Sexually-active male and female patients were required to use double-barrier (oral contraceptive plus barrier contraceptive) or must have undergone clinically documented total hysterectomy, ovariectomy, or tubal ligation.
  • Female patients of must have had a negative pregnancy test within 48 hours prior to start of study drug.
  • ≥ 8 weeks.
  • Signed by the patient prior to patient entry and any study procedure.

Exclusion criteria

Exclusion Criteria:

  • Receipt of imatinib or hydroxyurea (HU) prior to study entry or receipt of any agent within the last 6 months.
  • Patients who had received a second course of chemotherapy or radiotherapy, unless given as a single localized application of radio surgery.
  • In study STI571H2201 only, receipt of enzyme-inducing anticonvulsant drugs (EIACDs), eg, carbamazepine, phenobarbital, phenytoin, fosphenytoin, oxcarbazepine, or primidone. Previous EIACD should have been interrupted 4 weeks prior to study start.
  • Grade ≥ 2 peripheral edema or pulmonary or pericardial effusions or ascites of any grade.
  • Presence of any uncontrolled systemic infection.
  • Patients who were not a minimum of 12 weeks from completion of conventional external beam radiotherapy unless:

    1. There was new radiographical enhancement outside the field of radiation, or
    2. There was new pathological confirmation of recurrent tumor, or
    3. Progressive radiographical enhancement noted on post-radiotherapy/TMZ continue to worsen after an additional course of TMZ.
  • Evidence of intra-tumor hemorrhage on pretreatment diagnostic imaging, except for stable post-operative Grade 1 hemorrhage, patients with an excessive risk of an intracranial hemorrhagic event, and patients with history of central nervous system (excluding post-operative Grade 1) or intraocular bleed.
  • Patients who had undergone major surgery within 2 weeks prior to study entry or who had not recovered from prior major surgery, patients who had received chemotherapy within 4 weeks prior to study start, or who have not recovered from toxic effects of such therapy.
  • Impairment of gastrointestinal function or gastrointestinal disease that could significantly alter the absorption of imatinib.
  • Patients taking warfarin sodium.
  • Known history of (HIV) seropositivity; testing for HIV was not required at study entry.
  • For the purposes of MRI, patients with a pacemaker, ferromagnetic metal implants other than those approved as safe for use in MR scanners (eg, some types of aneurysm clips, shrapnel), patients suffering from uncontrollable claustrophobia, or those physically unable to fit into the machine (eg, obesity).
  • Patients considered by the investigator as unlikely to be compliant with the study, take the study medications, travel for the necessary assessment visits, or have other medical conditions likely to interfere with the study assessments.
  • Patients with another primary treated within the prior 3 years except excised squamous cell carcinomas of the skin and carcinoma in situ lesions of other organs which had been treated for cure.
  • Patients not able to provide reliable and who did not have a legal representative for healthcare decisions on their behalf.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    Imatinib 600 mg + hydroxyurea 1000 mg

    Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.

    Drug: Imatinib tablets · Drug: Hydroxyurea capsules

  • Experimental
    Imatinib 1000 mg + hydroxyurea 1000 mg

    Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.

    Drug: Imatinib tablets · Drug: Hydroxyurea capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With an Objective Overall Response (OOR)

    Patients with an OOR were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed with magnetic resonance imaging. A patient had a CR if the target tumors disappeared. A patient had a PR if there was a ≥ 50% reduction in the sum of the products of the largest perpendicular diameters of the target tumors compared to the baseline value. A best response of CR required at least 2 determinations of CR at least 4 weeks apart. A best response of PR required at least 2 determinations of PR or better at least 4 weeks apart (and not qualifying for CR).

    Time frame: Baseline to end of study (Month 24)

Secondary outcomes

  1. Duration of Objective Overall Response (OOR)

    Duration of OOR only included patients whose best overall response was complete response (CR) or partial response (PR). The start date was the date of the first documented response (CR or PR); the end date was the date of the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, the duration of OOR was censored at the time of the last OOR assessment.

    Time frame: Baseline to end of study (Month 24)

  2. Percentage of Patients Who Had Clinical Benefit

    Patients who had clinical benefit were patients with a best response of complete response (CR), partial response (PR), or stable disease (SD) lasting for more than 6 months from the start of treatment until the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. SD was defined as insufficient tumor shrinkage to qualify for PR or CR and no increase in lesions which would qualify as PD.

    Time frame: Baseline to end of study (Month 24)

  3. Percentage of Patients With Progression-free Survival at Months 6 and 12

    Progression-free survival (PFS) was defined as the time from the start of treatment to the date of the first documented disease progression (PD) or death due to any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, progression-free survival was censored at the time of the last overall response assessment.

    Time frame: Months 6 and 12

  4. Percentage of Patients Surviving at Months 6, 12, and 24

    Patients not known to have died were censored at the time of last survival follow-up.

    Time frame: Months 6, 12, and 24

  5. Number of Patients With at Least 1 Adverse Event

    An adverse event (AE) is any undesirable sign, symptom, or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. Study drug refers to imatinib or hydroxyurea. The study treatment is the combination of these two study drugs.

    Time frame: Baseline to end of study (Month 24)

07

Results

Posted May 16, 2011

Participant flow

Participant flow — Overall Study
MilestoneImatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mg
Started131100
Completed43
Not completed12797
Withdrew: Disease progression9573
Withdrew: Death1110
Withdrew: Adverse event126
Withdrew: Withdrawal by subject56
Withdrew: Administrative problems21
Withdrew: Protocol violation20
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPercentage of Patients With an Objective Overall Response (OOR)

Patients with an OOR were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed with magnetic resonance imaging. A patient had a CR if the target tumors disappeared. A patient had a PR if there was a ≥ 50% reduction in the sum of the products of the largest perpendicular diameters of the target tumors compared to the baseline value. A best response of CR required at least 2 determinations of CR at least 4 weeks apart. A best response of PR required at least 2 determinations of PR or better at least 4 weeks apart (and not qualifying for CR).

Time frame:
Baseline to end of study (Month 24)
Reported as:
Number · Percentage of participants
Percentage of Patients With an Objective Overall Response (OOR)
Percentage of participantsImatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mgAll Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg
Percentage of Patients With an Objective Overall Response (OOR)3.8 (1.3 to 8.7)3.0 (0.6 to 8.5)3.5 (1.5 to 6.7)
SecondaryDuration of Objective Overall Response (OOR)

Duration of OOR only included patients whose best overall response was complete response (CR) or partial response (PR). The start date was the date of the first documented response (CR or PR); the end date was the date of the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, the duration of OOR was censored at the time of the last OOR assessment.

Time frame:
Baseline to end of study (Month 24)
Reported as:
Median · Weeks
Duration of Objective Overall Response (OOR)
WeeksImatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mgAll Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg
Duration of Objective Overall Response (OOR)41.1 (32.1 to 53.6)32.1 (20.1 to NA)37.1 (32.1 to 53.6)
SecondaryPercentage of Patients Who Had Clinical Benefit

Patients who had clinical benefit were patients with a best response of complete response (CR), partial response (PR), or stable disease (SD) lasting for more than 6 months from the start of treatment until the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. SD was defined as insufficient tumor shrinkage to qualify for PR or CR and no increase in lesions which would qualify as PD.

Time frame:
Baseline to end of study (Month 24)
Reported as:
Number · Percentage of participants
Percentage of Patients Who Had Clinical Benefit
Percentage of participantsImatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mgAll Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg
Percentage of Patients Who Had Clinical Benefit9.9 (5.4 to 16.4)6.0 (2.2 to 12.6)8.2 (5.0 to 12.5)
SecondaryPercentage of Patients With Progression-free Survival at Months 6 and 12

Progression-free survival (PFS) was defined as the time from the start of treatment to the date of the first documented disease progression (PD) or death due to any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, progression-free survival was censored at the time of the last overall response assessment.

Time frame:
Months 6 and 12
Reported as:
Number · Percentage of participants
Percentage of Patients With Progression-free Survival at Months 6 and 12
Percentage of participantsImatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mgAll Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg
6 Months11.2 (5.7 to 16.6)9.9 (3.8 to 15.9)10.6 (6.5 to 14.7)
12 Months6.9 (2.4 to 11.3)3.3 (0.0 to 6.9)5.3 (2.3 to 8.3)
SecondaryPercentage of Patients Surviving at Months 6, 12, and 24

Patients not known to have died were censored at the time of last survival follow-up.

Time frame:
Months 6, 12, and 24
Reported as:
Number · Percentage of participants
Percentage of Patients Surviving at Months 6, 12, and 24
Percentage of participantsImatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mgAll Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg
6 Months49.2 (40.7 to 57.8)50.9 (40.9 to 61.0)50.0 (43.4 to 56.5)
12 Months28.5 (20.7 to 36.2)31.3 (21.9 to 40.7)29.7 (23.7 to 35.7)
24 Months10.7 (3.3 to 18.1)20.3 (11.8 to 28.9)13.9 (8.0 to 19.7)
SecondaryNumber of Patients With at Least 1 Adverse Event

An adverse event (AE) is any undesirable sign, symptom, or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. Study drug refers to imatinib or hydroxyurea. The study treatment is the combination of these two study drugs.

Time frame:
Baseline to end of study (Month 24)
Reported as:
Number · Participants
Number of Patients With at Least 1 Adverse Event
ParticipantsImatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mgAll Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg
Number of Patients With at Least 1 Adverse Event12998227

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib 600 mg + Hydroxyurea 1000 mg—62/131 (47.3%)122/131 (93.1%)
Imatinib 1000 mg + Hydroxyurea 1000 mg—53/99 (53.5%)95/99 (96%)
Most frequent serious events
Showing 10 of 125
Most frequent serious events
EventImatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mg
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)9/13112/99
General physical health deteriorationGeneral disorders10/1313/99
PneumoniaInfections and infestations7/1310/99
VomitingGastrointestinal disorders2/1315/99
ConvulsionNervous system disorders6/1315/99
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/1315/99
ThrombocytopeniaBlood and lymphatic system disorders6/1312/99
NauseaGastrointestinal disorders1/1314/99
HeadacheNervous system disorders4/1314/99
Intracranial pressure increasedNervous system disorders4/1314/99
Most frequent other events
Showing 10 of 51
Most frequent other events
EventImatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mg
NauseaGastrointestinal disorders49/13137/99
FatigueGeneral disorders40/13137/99
VomitingGastrointestinal disorders40/13122/99
HeadacheNervous system disorders33/13120/99
Oedema peripheralGeneral disorders31/13124/99
DiarrhoeaGastrointestinal disorders27/13116/99
ConstipationGastrointestinal disorders22/1319/99
DizzinessNervous system disorders13/13115/99
AnaemiaBlood and lymphatic system disorders19/13110/99
ThrombocytopeniaBlood and lymphatic system disorders19/13110/99

Baseline characteristics

Age Continuous
Age Continuous(years)Imatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mgTotal
Mean53.7 ± 11.952.8 ± 11.453.3 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Imatinib 600 mg + Hydroxyurea 1000 mgImatinib 1000 mg + Hydroxyurea 1000 mgTotal
Female523587
Male7965144
08

Study locations

1 site
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2006
First posted
Feb 13, 2006
Start
Feb 2006
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
May 16, 2011
Last update
May 16, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00290771
Lead sponsor
Novartis
First posted
Feb 13, 2006
Start date
Feb 2006
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
May 16, 2011
Last update
May 16, 2011

Study contacts

David Reardon, Dr.
principal investigator · Duke University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Imatinib · Hydroxyurea

Start the discussion